

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning at page 79, line 6, with the following rewritten paragraph:

The formulation of the present invention acts as a melatonin agonist or antagonist for mammals (for example, mouse, rat, hamster, rabbit, cat, dog, cow, sheep, monkey, human); and is useful as a melatonin receptor affinity composition, in particular, as a composition having a melatonin receptor agonist activity; and can be used for prevention and treatment of diseases which are liable to be influenced by melatonin, such as biological rhythm disorders and the like, for example, sleep-aware rhythm disorder, jet lag (jetlag), abnormality of physical condition by three change duty, severe depression of a season, genital and neuroendocrine disease, senile dementia, Alzheimer's disease, various disorders associated with aging (for example, antiaging), cerebral circulation disorder (for example, cerebral stroke), head injury, marrow damage, stress, epilepsy, cramp, uneasiness, depression, Parkinson's disease, high blood pressure, glaucoma, cancer, insomnia, diabetes and the like; and is also effective for immunoregulation, enhancement of cognition, ataractic or ovulation adjustment (for example, sterilization). The formulation of the present invention is used, for example, as a biological rhythm adjustment agent, preferably a therapeutic agent for somnipathy (for example, sleep leading agent and the like), sleep-aware rhythm adjustment agent (including sleep-aware rhythm adjusting action), and a prevention and treatment agent for time zone change syndrome, a so-called jet lag (jetlag). For instance, in the case of treatment of a somnopathist, a formulation of the present invention containing an about 1 to about 10% by weight of an active ingredient is applied on inside of the arm once a day for one month.